Literature DB >> 1350207

Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia.

R Pieters1, T Hongo, A H Loonen, D R Huismans, H J Broxterman, K Hählen, A J Veerman.   

Abstract

Although cellular drug resistance is considered to be an important cause of the poor prognosis of children with relapsed acute lymphoblastic leukaemia (ALL), the knowledge of drug resistance in these patients is very limited. Different aspects of drug resistance were studied in 17 children with relapsed ALL. The in vitro sensitivity profile was determined using the MTT assay. Cells from relapsed children were significantly more resistant to 6-thioguanine, prednisolone, cytosine arabinoside, daunorubicin (DNR), mustine-HCl and mafosfamide but not to L-asparaginase and vincristine (VCR) than cells from 41 children with ALL at initial diagnosis. Some relapsed patients showed a general drug resistance while others were resistant to only 1-3 drugs. The relevance of the multidrug resistance (MDR) model was analysed: In all DNR- and VCR resistant cases a co-resistance to drugs not involved in the MDR model was found. P-glycoprotein was not detected in any of 28 untreated and 14 relapsed samples tested. VCR- and DNR accumulation in the most resistant cells were not lower than in sensitive cells. Resistance modifiers did not potentiate the cytotoxicity of VCR and DNR. We conclude that resistance to anthracyclines and vinca alkaloids in childhood relapsed ALL is not due to P-glycoprotein mediated MDR. Different types of drug resistance varying from a resistance to only one drug to a general chemoresistance, can be detected in children with relapsed ALL. VCR and L-asparaginase seemed to be only infrequently involved in drug resistance. Knowledge of drug resistance might lead to more effective and less toxic therapies for children with relapsed ALL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350207      PMCID: PMC1977370          DOI: 10.1038/bjc.1992.146

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  [Anticancer drug sensitivity test using the short-term microplate culture and MTT dye reduction assay].

Authors:  T Hongo; Y Fujii; Y Mizuno; S Haraguchi; T O Yoshida
Journal:  Gan To Kagaku Ryoho       Date:  1987-02

2.  Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.

Authors:  P Ubezio; M Limonta; M D'Incalci; G Damia; G Masera; G Giudici; J S Wolverton; W T Beck
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

3.  Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies.

Authors:  M C Bird; A G Bosanquet; S Forskitt; E D Gilby
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

4.  Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay.

Authors:  A G Bosanquet
Journal:  Lancet       Date:  1991-03-23       Impact factor: 79.321

Review 5.  Clinical pharmacology of cancer chemotherapy in children.

Authors:  W E Evans; W P Petros; M V Relling; W R Crom; T Madden; J H Rodman; M Sunderland
Journal:  Pediatr Clin North Am       Date:  1989-10       Impact factor: 3.278

6.  Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.

Authors:  W S Dalton; T M Grogan; J A Rybski; R J Scheper; L Richter; J Kailey; H J Broxterman; H M Pinedo; S E Salmon
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

7.  Detection of P-glycoprotein in human leukemias using monoclonal antibodies.

Authors:  J Mattern; T Efferth; M Bak; A D Ho; M Volm
Journal:  Blut       Date:  1989-04

8.  Perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C.

Authors:  L M Weisenthal; Y Z Su; T E Duarte; P L Dill; R A Nagourney
Journal:  Cancer Treat Rep       Date:  1987-12

9.  An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia.

Authors:  T Hongo; Y Fujii; Y Igarashi
Journal:  Cancer       Date:  1990-03-15       Impact factor: 6.860

10.  In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood.

Authors:  G J Kaspers; R Pieters; C H Van Zantwijk; P A De Laat; F C De Waal; E R Van Wering; A J Veerman
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

View more
  10 in total

Review 1.  The importance of phase I/II trials in pediatric oncology.

Authors:  C A MacArthur; T Vietti
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 2.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 4.  Cellular drug resistance in childhood leukemia.

Authors:  A J Veerman; G J Kaspers; R Pieters
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

5.  6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Authors:  Natalia Issaeva; Huw D Thomas; Tatjana Djureinovic; Tatjana Djurenovic; Janneke E Jaspers; Ivaylo Stoimenov; Suzanne Kyle; Nicholas Pedley; Ponnari Gottipati; Rafal Zur; Kate Sleeth; Vicky Chatzakos; Evan A Mulligan; Cecilia Lundin; Evgenia Gubanova; Ariena Kersbergen; Adrian L Harris; Ricky A Sharma; Sven Rottenberg; Nicola J Curtin; Thomas Helleday
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

6.  Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia.

Authors:  A Sauerbrey; F Zintl; M Volm
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

Review 7.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

8.  In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.

Authors:  E Klumper; R Pieters; M L den Boer; D R Huismans; A H Loonen; A J Veerman
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

9.  Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.

Authors:  H Fridborg; B Jonsson; P Nygren; K Csoka; K Nilsson; G Oberg; J Kristensen; J Bergh; B Tholander; L Olsen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

10.  P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia.

Authors:  A Sauerbrey; F Zintl; M Volm
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.